CEREBROLYSIN is a neuropeptide and hydrolysate of a porcine brain tissue developed in 1949 and first approved for medical use in 1954. Cerebrolysin in modern days is widely administered in 50 countries worldwide in Europe and Asia and used to improve the cognitive abilities by stimulating the regeneration of the nervous system. There is a vast array of studies (around 200) and human trials carried out in the past 15 years. The natural repair and recovery processes in the Central Nervous System (CNS) that start immediately upon injury and play an important role in the continuous defense against neurodegeneration in chronic CNS disorders (e.g. Alzheimer’s disease). Cerebrolysin has shown to modify two major signalling pathways: the neurotrophic factor (NTF) and sonic hedgehog (Shh) signalling pathway. These pathways regulate on a molecular level the cellular processes of neurogenesis, angiogenesis, dendrite arborisation, axonal sprouting, myelination, and remodelling of the neurovascular unit, thereby supporting the maintenance and repair of the neuronal network.